Degussa AG divests pharmaceutical interests
Business Review Editor
Abstract
Degussa divested its pharmaceutical business for around €6.5 B. Degussa had sold ASTA oncology business to Baxter International, Viatris GmbH to Advent International and also AWD.pharma. The company had planned to sell its MainGen GmbH to CRYO-CELL Europe.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.